Lineage Therapeutics Announces Early Phase 2 Data for IPF Treatment LTI-03
RNTX Rein Therapeutics Inc
$0.36 -10.90%
View chart & analysis → - 1Lineage Therapeutics announced 12-week blinded analysis results from the Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis (IPF).
- 2Among 24 evaluable patients at week 12, a 33% improvement in forced vital capacity (FVC) from baseline was recorded.
- 3Rein recorded a net loss of $5.5 million for the third quarter ended September 30, 2026.
So what's the key point?
Lineage Therapeutics released interim clinical trial results for a lung disease treatment. Lung function improved by 33% for 24 patients, and the company reported a $5.5 million loss.
Source Clinical Trials Arena +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.